MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Key Terms

monoclonal antibodies medical

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

intrabodies medical

Intrabodies are lab-designed antibody fragments meant to operate inside living cells to bind and neutralize specific proteins, like placing a custom clamp on a malfunctioning gear inside a machine to stop it from causing damage. For investors, they represent a promising therapeutic approach that can tackle disease mechanisms traditional drugs often cannot reach, offering potential upside for drug pipelines while carrying notable delivery, safety and development risks that influence valuation and timelines.

tdp-43 medical

TDP-43 is a protein inside cells that helps regulate how genetic instructions are used; when it misfolds or accumulates into clumps in brain or spinal cord cells, it is linked to neurodegenerative conditions like ALS and some dementias. For investors, TDP-43 matters because it is a clear biological target for diagnostics and therapies—detecting or stopping its abnormal behavior could change patient care and create commercial value, similar to fixing a faulty part in a complex machine.

amyotrophic lateral sclerosis medical

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

frontotemporal dementia medical

A progressive neurological disorder that damages the brain regions controlling behavior, personality, language and movement, causing gradual changes in judgment, speech and social skills—like a control center in the head slowly losing its ability to coordinate those functions. It matters to investors because it creates demand for diagnostics, therapies and long‑term care, shapes clinical trial risk and regulatory outcomes, and can influence revenue prospects for pharmaceutical, biotech and medical services companies.

alzheimer’s disease medical

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

biorxiv technical

bioRxiv is an online repository where researchers post biology and life‑sciences preprints—early versions of research papers shared before formal peer review. Investors watch bioRxiv because it can reveal new scientific findings or drug data ahead of official publications or regulatory filings, like reading a company’s draft report; however, its contents are preliminary and should be treated cautiously until validated by peer review or regulatory confirmation.

doi technical

A DOI (Digital Object Identifier) is a unique, permanent identifier assigned to a specific digital document, such as a research paper, regulatory filing, or clinical report. Think of it as an ISBN or permanent web address that always points to the original source; investors use DOIs to reliably locate and verify primary documents behind claims, supporting due diligence and tighter assessment of scientific, regulatory, or technical evidence cited in corporate announcements.

VICTORIA, British Columbia--(BUSINESS WIRE)-- MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease.

The work demonstrates MindWalk’s ability to discriminate with structural precision between toxic protein conformations and their healthy counterparts, a long-standing challenge in neurodegenerative drug development. By defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, the Company is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets.

“This discovery validates our platform strategy,” said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk. “We are identifying disease-defining protein states and translating that insight into selective, validated assets with traceable biological evidence behind them.”

Beyond the specific biology, the study provides external validation of MindWalk’s platform capabilities in a client-driven setting and reinforces the Company’s position as a trusted discovery partner for complex neurodegenerative programs.

The full scientific study, Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43, is available on bioRxiv (DOI: 10.1101/2025.06.10.658846).

About MindWalk

MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by its patented HYFT^® technology and LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. The platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the Company’s discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities.

Forward-looking statements are based on management’s current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the Company’s reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the Company’s ability to execute its strategy, secure resources, and manage growth.

Except as required by law, MindWalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260114327020/en/

Investor Contact

Louie Toma, CPA, CFA

Managing Director, CoreIR

investors@mindwalkAI.com

Source: MindWalk Holdings Corp.